Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Dubsky

Showing results (31-40 of 47) with videos related to

Pageof 5
Sort By:
British Journal of Cancer|December 1, 2011
Impact of anti-HER2 therapy on overall survival in HER2-overexpressing breast cancer patients with brain metastasesR Bartsch, A Berghoff, U Pluschnig, et al.
Breast Cancer Research and Treatment|April 25, 2016
Prognostic impact of breast cancer subtypes in elderly patientsE S Bergen, C Tichy, A S Berghoff, et al.
Cancer Treatment Reviews|December 24, 2014
Optimising translational oncology in clinical practice: strategies to accelerate progress in drug developmentR Stahel, J Bogaerts, F Ciardiello, et al.
ESMO Open|January 5, 2021
A clinical validation study of MammaPrint in hormone receptor-positive breast cancer from the Austrian Breast and Colorectal Cancer Study Group 8 (ABCSG-8) biomarker cohortP Dubsky, L Van't Veer, M Gnant, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 4, 2015
Identifying clinically relevant prognostic subgroups of postmenopausal women with node-positive hormone receptor-positive early-stage breast cancer treated with endocrine therapy: a combined analysis of ABCSG-8 and ATAC using the PAM50 risk of recurrence score and intrinsic subtypeM Gnant, I Sestak, M Filipits, et al.
ESMO Open|August 9, 2021
ESR1, PGR, ERBB2, and MKi67 mRNA expression in postmenopausal women with hormone receptor-positive early breast cancer: results from ABCSG Trial 6M Filipits, M Rudas, C F Singer, et al.
British Journal of Cancer|January 12, 2012
Brain metastases free survival differs between breast cancer subtypesA Berghoff, Z Bago-Horvath, C De Vries, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 5, 2012
EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancerP Dubsky, M Filipits, R Jakesz, et al.
British Journal of Cancer|March 21, 2013
Efficacy of tamoxifen ± aminoglutethimide in normal weight and overweight postmenopausal patients with hormone receptor-positive breast cancer: an analysis of 1509 patients of the ABCSG-06 trialG Pfeiler, H Stöger, P Dubsky, et al.
British Journal of Cancer|October 26, 2013
The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2- breast cancer patientsP Dubsky, J C Brase, R Jakesz, et al.
Pageof 5

Showing results (31-40 of 47) with videos related to

Sort By:
Pageof 5
British Journal of Cancer|December 1, 2011
Impact of anti-HER2 therapy on overall survival in HER2-overexpressing breast cancer patients with brain metastasesR Bartsch, A Berghoff, U Pluschnig, et al.
Breast Cancer Research and Treatment|April 25, 2016
Prognostic impact of breast cancer subtypes in elderly patientsE S Bergen, C Tichy, A S Berghoff, et al.
Cancer Treatment Reviews|December 24, 2014
Optimising translational oncology in clinical practice: strategies to accelerate progress in drug developmentR Stahel, J Bogaerts, F Ciardiello, et al.
ESMO Open|January 5, 2021
A clinical validation study of MammaPrint in hormone receptor-positive breast cancer from the Austrian Breast and Colorectal Cancer Study Group 8 (ABCSG-8) biomarker cohortP Dubsky, L Van't Veer, M Gnant, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 4, 2015
Identifying clinically relevant prognostic subgroups of postmenopausal women with node-positive hormone receptor-positive early-stage breast cancer treated with endocrine therapy: a combined analysis of ABCSG-8 and ATAC using the PAM50 risk of recurrence score and intrinsic subtypeM Gnant, I Sestak, M Filipits, et al.
ESMO Open|August 9, 2021
ESR1, PGR, ERBB2, and MKi67 mRNA expression in postmenopausal women with hormone receptor-positive early breast cancer: results from ABCSG Trial 6M Filipits, M Rudas, C F Singer, et al.
British Journal of Cancer|January 12, 2012
Brain metastases free survival differs between breast cancer subtypesA Berghoff, Z Bago-Horvath, C De Vries, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 5, 2012
EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancerP Dubsky, M Filipits, R Jakesz, et al.
British Journal of Cancer|March 21, 2013
Efficacy of tamoxifen ± aminoglutethimide in normal weight and overweight postmenopausal patients with hormone receptor-positive breast cancer: an analysis of 1509 patients of the ABCSG-06 trialG Pfeiler, H Stöger, P Dubsky, et al.
British Journal of Cancer|October 26, 2013
The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2- breast cancer patientsP Dubsky, J C Brase, R Jakesz, et al.
Pageof 5